Get the Stockscreener App
13.44
1.39%
-0.19
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $13.44, with a volume of 5.92M.
It is down -1.39% in the last 24 hours and down -14.39% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$13.63
Open:
$13.31
24h Volume:
5.92M
Relative Volume:
0.59
Market Cap:
$15.47B
Revenue:
$14.29B
Net Income/Loss:
$-3.51B
P/E Ratio:
-4.5401
EPS:
-2.9603
Net Cash Flow:
$1.85B
1W Performance:
+0.52%
1M Performance:
-14.39%
6M Performance:
+32.94%
1Y Performance:
+55.20%
1-Day Range:
$13.28
$13.65
1-Week Range:
$12.87
$13.76
52-Week Range:
$6.85
$16.47
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
13.44 | 15.47B | 14.29B | -3.51B | 1.85B | -2.9603 |
TAK
Takeda Pharmaceutical Co Adr
|
18.74 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
117.94 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.93 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.08 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
564.81 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Upgrade | UBS | Neutral → Buy |
| Jan-16-26 | Upgrade | Argus | Hold → Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-15-25 | Initiated | Truist | Buy |
| Jun-06-25 | Initiated | Goldman | Neutral |
| Jul-19-24 | Resumed | Jefferies | Buy |
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
Viatris Inc (VIA.HM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Viatris (VTRS) price target increased by 10.80% to 15.70 - MSN
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
Viatris (VTRS) 2026 proxy details $14.3B revenue, board refresh and key votes - Stock Titan
(VTRS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Viatris at $14: A Double-Digit FCF Yield Hiding in Plain Sight - Investing.com
Viatris Inc. (VTRS) Stock Forecasts - finance.yahoo.com
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris Named a Great Place To Work in India for the Fifth Consecutive Year - businesswireindia.com
Is Effexor’s First-in-Class GAD Approval in Japan Altering The Investment Case For Viatris (VTRS)? - simplywall.st
VTRS PE Ratio & Valuation, Is VTRS Overvalued - Intellectia AI
Viatris sets long-term targets ahead of investor event - MSN
ACC26 conference visit sees Viatris stock decline amid persistent negative momentum and oversold levels - tradersunion.com
TeraWulf, Viatris, MGM, Nucor, Best Buy Shake-Up - TipRanks
Viatris at $14: A Double-Digit FCF Yield Hiding in Plain Sight - GuruFocus
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Vanguard (VTRS) Amendment No.3: Reports 0% Beneficial Ownership After Realignment - Stock Titan
(VTRS.O) | Stock Price & Latest News - Reuters
Empowering the Front Lines: How the NCD Academy Is Transforming Community Level Care - Viatris
Viatris Inc. (VTRS) Discusses Long-Term Growth Outlook and Portfolio Strategy Across Generics, Established Brands and Innovative MedicinesSlideshow (NASDAQ:VTRS) 2026-03-25 - Seeking Alpha
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Viatris Named to 3BL’s 100 Best Corporate Citizens of 2023 Ranking - CSRwire
Viatris Insider Sold Shares Worth $283,539, According to a Recent SEC Filing - marketscreener.com
Analysts Are Bullish on Top Healthcare Stocks: Siemens Healthineers AG (SEMHF), Viatris (VTRS) - The Globe and Mail
Top Viatris Executive Makes Notable Move With Insider Stock Sale - TipRanks
Viatris Inc officer Campbell sells $283k in shares - Investing.com
Viatris (VTRS) insider trims stake with 21,350-share open-market sale - Stock Titan
Global cardiovascular leaders convene as Viatris joins ACC26 event in New Orleans - Traders Union
Viatris sees positive top-line phase 3 results for night driving impairment asset - MSN
[144] Viatris Inc SEC Filing - stocktitan.net
Barclays raises Viatris stock price target on pipeline potential By Investing.com - Investing.com Australia
Barclays raises Viatris stock price target on pipeline potential - Investing.com
VTRS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Viatris’ Effexor Approved in Japan for Generalized Anxiety Disorder - contractpharma.com
Barclays Adjusts Viatris Price Target to $17 From $15, Maintains Overweight Rating - marketscreener.com
Viatris Stock: Is VTRS Outperforming the Health Care Sector? - Yahoo Finance
Viatris Says Japan Regulator Approves Effexor for Generalized Anxiety Disorder in Adults - marketscreener.com
Viatris wins Japan approval for Effexor to treat anxiety disorder - Investing.com
Japan clears Effexor as first approved GAD treatment for adults - Stock Titan
Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD) - Sahm
Levi & Korsinsky Notifies Shareholders of Viatris Inc.(VTRS) of a Class Action Lawsuit and an Upcoming Deadline - The National Law Review
Viatris Advances Innovative Portfolio with Approval of Effexor in Japan for Adults with Generalized Anxiety Disorder (GAD) - Bitget
How (VTRS) Movements Inform Risk Allocation Models - Stock Traders Daily
What are analysts saying about Viatris Inc (VTRS) stock? - MSN
Viatris shares break six-session winning streak - MSN
Will Viatris’ 2030 Capital Return And Growth Blueprint Change Viatris' (VTRS) Narrative - Yahoo Finance
Jefferies Keeps Their Buy Rating on Viatris (VTRS) - The Globe and Mail
Theravance's Q4 Earnings and Revenues Miss Estimates - TradingView
Viatris: Is It A Credible Turnaround Or Overly Optimistic 2030 Plan? - Seeking Alpha
Will Viatris’ 2030 Capital and R&D Framework Reset the Core Investment Narrative for VTRS? - simplywall.st
Investor Alert: Robbins LLP Informs Stockholders of the Viatris Inc. Class Action - GuruFocus
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
8.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):